NOVOB Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 86.71 |
| 52 Week High | DKK 87.51 |
| 52 Week Low | DKK 59.42 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | -0.92% |
| 1 Year Change | 45.72% |
| 3 Year Change | 175.26% |
| 5 Year Change | 278.02% |
| Change since IPO | 74.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVOB | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 0.5% |
| 1Y | 45.7% | 6.2% | 3.5% |
Return vs Industry: NOVOB exceeded the Swiss Pharmaceuticals industry which returned -9.5% over the past year.
Return vs Market: NOVOB exceeded the Swiss Market which returned -0.9% over the past year.
Price Volatility
| NOVOB volatility | |
|---|---|
| NOVOB Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in CH Market | 6.8% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: NOVOB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOVOB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 61,412 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.
Novo Nordisk A/S Fundamentals Summary
| NOVOB fundamental statistics | |
|---|---|
| Market cap | CHF 388.31b |
| Earnings (TTM) | CHF 9.54b |
| Revenue (TTM) | CHF 27.18b |
40.7x
P/E Ratio14.3x
P/S RatioIs NOVOB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVOB income statement (TTM) | |
|---|---|
| Revenue | DKK 214.49b |
| Cost of Revenue | DKK 34.01b |
| Gross Profit | DKK 180.48b |
| Other Expenses | DKK 105.17b |
| Earnings | DKK 75.31b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Jan 31, 2024
| Earnings per share (EPS) | 16.89 |
| Gross Margin | 84.14% |
| Net Profit Margin | 35.11% |
| Debt/Equity Ratio | 28.5% |
How did NOVOB perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield42%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/06 03:45 |
| End of Day Share Price | 2023/09/08 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Nordisk A/S is covered by 71 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |